HEK 293 cells

Avirmax Biopharma Inc. to Present at the 2024 ARVO Annual Meeting in Seattle

Retrieved on: 
Monday, April 1, 2024
Research, Neuroprotection, Sf9, Glaucoma, ARVO, HEK293, HEK 293 cells

HAYWARD, Calif., April 1, 2024 /PRNewswire/ -- Avirmax Biopharma Inc., will make three scientific presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle between May 5th and 9th, 2024.

Key Points: 
  • HAYWARD, Calif., April 1, 2024 /PRNewswire/ -- Avirmax Biopharma Inc., will make three scientific presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle between May 5th and 9th, 2024.
  • ARVO is the largest international society dedicated to ophthalmology and vision-related topics.
  • Dr. Shengjiang Liu, Ph.D. Chief Executive and Scientific Officer, is invited to present "Systematic comparison of rAAV vectors manufactured using large-scale suspension cultures of Sf9 and HEK293 cells", at the 2024 ARVO Symposium on "Developing gene therapy for glaucoma neuroprotection: Opportunities and challenges", May 9, 8 – 10 am.
  • In addition to the invited talk, there will be two more scientific presentations from Avirmax Biopharma and an exhibitor booth #1604 to showcase the latest progress and data package:

Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on: 
Tuesday, May 16, 2023
Tissue, Mouse, B cell, HEK 293 cells, Gene, ERG, RS1, Drug discovery, New product development, Mutation, RNA, AAV, CRE, Immunohistochemistry, Messenger, ABCA4, Animal, Ophthalmology, Cell, ISCB Senior Scientist Award, HEK293, Research, FDA, Therapy, Society, Treatment, Vaccine, Medical device, Silviculture

CLEVELAND, May 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced new data regarding three internally developed preclinical gene therapy product candidates from its adeno-associated virus (AAV) ophthalmology program that will be presented at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place from May 16-20, 2023 in Los Angeles, CA.

Key Points: 
  • CLEVELAND, May 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced new data regarding three internally developed preclinical gene therapy product candidates from its adeno-associated virus (AAV) ophthalmology program that will be presented at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place from May 16-20, 2023 in Los Angeles, CA.
  • Cre-mediated recombination of ABCA4 was confirmed by mRNA sequencing of RNA from transfected HEK293 cells and AAV-dosed animals.
  • RS1 expression was associated with improvement in cone photoreceptor density and increased thickness of the photoreceptor outer nuclear layer.
  • Following intravitreal injection in wild type mice, variants 1 and 7 showed robust protein expression.

FUJIFILM Irvine Scientific Launches HEK293 Feed, Specifically Designed for Viral Vector Production

Retrieved on: 
Tuesday, January 10, 2023
Other Manufacturing, Research, Infectious Diseases, Genetics, Manufacturing, Biotechnology, Health, Pharmaceutical, Science, AAV, FDA, Catalog, GMP, HEK 293 cells, Vaccine

The chemically defined, nutrient-based HEK293-specific feed medium is designed to boost adeno-associated viral vector (AAV) production for gene therapy applications and viral vector-based vaccines.

Key Points: 
  • The chemically defined, nutrient-based HEK293-specific feed medium is designed to boost adeno-associated viral vector (AAV) production for gene therapy applications and viral vector-based vaccines.
  • For manufacturers, it is imperative to boost viral vector production to meet supply demands for vaccine and gene therapy manufacture.
  • It is chemically defined and formulated to deliver consistent performance while increasing viral vector production in HEK293 cells grown in suspension and at scale.
  • We developed BalanCD HEK293 Viral Feed specifically to increase yields and help manufacturers maximize production, and lower cost of goods related to viral vector-based drug programs.” said Erik Vaessen, chief business officer, FUJIFILM Irvine Scientific.

The Native Antigen Company Expands Infectious Disease Portfolio to Include Sudan Ebolavirus Boniface 1976 Glycoprotein

Retrieved on: 
Thursday, December 8, 2022
Medical Devices, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Antigen, Ebolavirus, SEBOV, Infection, HEK 293 cells, Research, Ebola, Disease, Antibody, Cell, Human, Vaccine, Immunoassay, Mortality, Health, EBOV, Sudan ebolavirus

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the worlds leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial release of its Sudan Ebolavirus Boniface 1976 Glycoprotein (SEBOV GP).

Key Points: 
  • The Native Antigen Company (part of LGC Clinical Diagnostics), one of the worlds leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial release of its Sudan Ebolavirus Boniface 1976 Glycoprotein (SEBOV GP).
  • Sudan Ebolavirus is a species of ebolavirus responsible for severe disease in humans, Ebola haemorrhagic fever, for which there are currently no licensed vaccines or treatments available.
  • The Native Antigen Companys SEBOV GP is designed for use in immunoassay and vaccine development to support research into the deadly disease.
  • For further information about The Native Antigen Companys Sudan Ebolavirus Boniface 1976 Glycoprotein, please visit: https://thenativeantigencompany.com/products/ebola-virus-envelope-glycop...

QIAGEN adds new biopharma products to QIAcuity digital PCR portfolio and launches Expert Custom Assay Design Service

Retrieved on: 
Wednesday, July 27, 2022
Software, Biotechnology, Pharmaceutical, General Health, Health, Technology, Genetics, Other Technology, DNA, Escherichia coli, HEK293, Biopharma LLC, Center, Education, Communities and Justice Directorates, Protein, U.S. Securities and Exchange Commission, Molecular diagnostics, CHO, Real-time, NYSE, SEC, QGEN, Research, Drug discovery, Compliance, Software, Solution, Gene, Title 21 CFR Part 11, Polymerase, Knowledge, GMP, Catalog, Automation, Central business district, Drug development, Technology, CGT, FDA, Senior, Blood, CFR, Life, HEK 293 cells, Growth, PCR, Workflow, Budget, AAV, RNA, Vaccine, Medical device, Fine chemical, QIAGEN, Insight, Academy, Pharma

A new version of the QIAcuity Software Suite has been released with expanded functionality to support good manufacturing practice (GMP) compliance.

Key Points: 
  • A new version of the QIAcuity Software Suite has been released with expanded functionality to support good manufacturing practice (GMP) compliance.
  • QIAcuitys approach to digital PCR is based on using nanoplates to partition the samples more quickly than other systems.
  • Our custom assays for dPCR build on decades of expertise in assay design for traditional qPCR.
  • The Expert Custom Assay Design Service will extend customer choice beyond the existing catalog of assays, especially in key application areas that require simultaneous detection of up to five molecular markers.

Capsida Biotherapeutics Presents Data Demonstrating Unique Industry-Leading Technology and Capabilities With Potential to Treat Both Rare and Common Diseases at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on: 
Wednesday, May 18, 2022
Engineering, Company, Annual general meeting, Capsid, HEK 293 cells, Washington Convention Center, Multimedia, AbbVie, Automation, HEK293, Translation, Liver, Society, Research, Patent, Gene, Efficiency, CNS, Brain, Spinal cord, California Institute for Quantitative Biosciences, AAV, Kaay Raav Tumhi, Intellectual property, Biotechnology, CRISPR, Walter, Central nervous system, Walter E. Washington Convention Center, Therapy, Cell, Transfection, Bioreactor, Tissue, Vaccine, Mobile phone, Technology

THOUSAND OAKS, Calif., May 18, 2022 /PRNewswire/ -- Capsida Biotherapeutics ("Capsida"), the only fully integrated gene therapy platform company that through intravenous (IV) delivery of a single, engineered capsid can target single or multiple organs simultaneously while limiting exposure to non-targeted organs, today announced four posters delivered at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. Capsida's approach unlocks the potential to treat both rare and common diseases across all ages.

Key Points: 
  • Capsida's approach unlocks the potential to treat both rare and common diseases across all ages.
  • The ASGCT Annual Meeting is being held virtually and in person May 16-19, 2022, in Washington, D.C. at the Walter E. Washington Convention Center.
  • The totality of these data, along with achievements in our process development and manufacturing processes, will allow us to rapidly advance gene therapies into the clinic."
  • The company is exploring using the technology across a broad range of rare and more common genetic and sporadic disorders.

AGTC to Present Preclinical Research Supporting Gene Therapy Platform in Frontotemporal Dementia at the 25th Annual Meeting of the American Society of Gene & Cell Therapy

Retrieved on: 
Monday, May 2, 2022
ACHM, COVID-19, Drug development, GRN, Forward-looking statement, Capsid, FTD, Mutation, Nasdaq, Stargardt disease, B cell, GLOBE, CNS, HEK 293 cells, Applied Genetic Technologies Corporation, Cell, Cerebrospinal fluid, AAV, ICM, Retina, Annual report, Poster, Central nervous system disease, Patient, A4, Achromatopsia, ATP, Gene, Neurodegeneration, FDT, Risk, Therapy, Frontotemporal dementia, Gene expression, Form 10-K, Primate, Neurotology, Dementia, Optogenetics, Society, Disease, SEC, ABCA4, Technology, Research, Central nervous system, Vaccine, Antibiotics, Granulin, D.C

We believe the preclinical findings in frontotemporal dementia are particularly encouraging and look forward to continuing our research to support a potential future Investigational New Drug Application filing.

Key Points: 
  • We believe the preclinical findings in frontotemporal dementia are particularly encouraging and look forward to continuing our research to support a potential future Investigational New Drug Application filing.
  • Results support the feasibility of augmenting progranulin expression via AAV-GRN gene therapy as a potential treatment for FDT caused by GRN mutations.
  • AGTCs most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with inherited retinal diseases.
  • Also, forward-looking statements represent management's plans, estimates, assumptions and beliefs only as of the date of this release.

Twist Bioscience Launches High Throughput Antibody Production Platform

Retrieved on: 
Thursday, April 28, 2022
Software, Research, Other Health, Technology, Medical Devices, Infectious Diseases, Genetics, Science, Nanotechnology, Biotechnology, Other Technology, Health, Other Science, Antibody, HEK 293 cells, Drug discovery, DNA, U.S. Securities and Exchange Commission, CEO, NGS, Silicon, Private Securities Litigation Reform Act, Efficiency, Technology, Risk, Martek Biosciences Corporation, Boston, Security (finance), CSO, Friends, Engineering, Doctor of Philosophy, NASDAQ, Synthetic biology, Genomics, SEC, Biology, Agriculture, Twist Bioscience, Vaccine, Fine chemical

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of synthetic DNA using its silicon platform, today announced the launch of the Twist High Throughput Antibody Production, a gene-to-antibody production platform that enables customers to turn candidate DNA sequences into purified antibodies for therapeutic discovery and screening applications.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of synthetic DNA using its silicon platform, today announced the launch of the Twist High Throughput Antibody Production, a gene-to-antibody production platform that enables customers to turn candidate DNA sequences into purified antibodies for therapeutic discovery and screening applications.
  • Similarly, this new offering could have the same impact on high throughput antibody screening, i.e.
  • The Twist High Throughput Antibody Production provides a comprehensive and efficient solution to antibody production and purification.
  • Twists silicon-based DNA synthesis platform enables the simultaneous production of up to thousands of antibody genes, which enables flexible production of tens to thousands of distinct antibodies.

Primestone Partners Names Relocation-Veteran Michael Hekking As Chief Operating Officer (COO) Of Primestone Housing Solutions

Retrieved on: 
Thursday, October 7, 2021
Avis, Efficiency, HEK 293 cells, Witherell, Citibank, Solution, LLC, Marketing, Growth, Industry, Realogy, Housing, Freddie Mac, COO, Morgan Stanley, EMEA, SIRVA, Government, Organization, Technology, Lehman Brothers, Fortune 500, Financial services, Management

NEW YORK, Oct. 7, 2021 /PRNewswire/ -- Primestone Partners LLC, a New York-based, consulting and corporate housing management firm, announced today that relocation and corporate housing executive Mike Hekking has been named Chief Operating Officer of the Primestone Housing Solutions division.

Key Points: 
  • NEW YORK, Oct. 7, 2021 /PRNewswire/ -- Primestone Partners LLC, a New York-based, consulting and corporate housing management firm, announced today that relocation and corporate housing executive Mike Hekking has been named Chief Operating Officer of the Primestone Housing Solutions division.
  • The Primestone Housing Solutions team is a group of seasoned professionals with extensive experience in the housing industry.
  • Primestone Housing Solutions has a portfolio of properties in more than 36 markets both nationally and internationally.
  • In this new role, Hekking will be responsible for leading Primestone Housing Solutions' global operations.

DGAP-News: CEVEC Pharmaceuticals GmbH: CEVEC closes growth financing round to serve strong demand in viral vector technologies for cell and gene therapies

Retrieved on: 
Tuesday, July 27, 2021
Branches of biology, Biology, Life sciences, Gene delivery, Molecular biology, Biotechnology, Bioethics, Emerging technologies, HEK 293 cells, Viral vector, Gene therapy, Vector, CEVEC, the gene therapy market, CEVEC, THE GENE THERAPY MARKET

CEVEC also announced that the ELEVECTA(R) Technology is currently being implemented in HEK293 as a second host cell type.

Key Points: 
  • CEVEC also announced that the ELEVECTA(R) Technology is currently being implemented in HEK293 as a second host cell type.
  • As HEK293 is the most widely used host cell line in gene therapy manufacturing, CEVEC expects to see a significant increase in demand from clients and partners.
  • "We are delighted to be part of this financing round with the aim of accelerating the company's growth and becoming market leader for stable vector manufacturing technologies in cell and gene therapies."
  • The company's product portfolio comprises platform technologies for gene therapy viral vectors, vaccines and complex recombinant proteins.